ALVAL — Valbiotis SA Share News
0.000.00%
Last trade - 00:00- €18.60m
- €11.17m
- €0.91m
Brief: Valbiotis To Launch Phase II/III REVERSE-IT Clinical Study On TOTUM-63
Brief: Valbiotis FY Operating Loss Widens To 5.2 Million Euros
Brief: Valbiotis Accelerates Its Pipeline Clinical Development
Brief: Valbiotis Launches Late Stage Development Phase Of Totum-63
Brief: Valbiotis Signs Global Strategic Partnership With Nestlé Health Science
Brief: Valbiotis Requests Suspension Of Shares From Euronext Growth
Brief: Valbiotis Launches Capital Increase Of 7.2 Million Euros
Brief: Valbiotis Presents Positive Results From A Study On TOTUM-63
Brief: Valbiotis Publishes Additional Results From Phase IIa Study Of Valedia
Brief: Valbiotis Reports H1 Operating Loss Of 2.6 Million Euros
Brief: Valbiotis: Positive Results From Phase IIa Clinical Study Of Valedia
Brief: VALBIOTIS Presents Novel Data about TOTUM-63, Metabolic Diseases Prevention
Brief: Valbiotis Succeeds In Industrial Production Of Valedia
Brief: Valbiotis Receives Grants For A Total Amount Of 885,000 Euros
Brief: Valbiotis FY Recurring Operating Loss Widens to 4.8 Million Euros
Brief: Valbiotis Obtains The European Patent For VALEDIA
Brief: Valbiotis: Expansion Of Application For Valedia To Include NASH Prevention
Brief: Valbiotis Confirms Publication Of Results From Study Evaluating Valedia By Mid-2019
Brief: Valbiotis Signs Scientific Partnership With CarMeN